Investments
2Portfolio Exits
1Partners & Customers
10Medison Pharma Web Traffic
Medison Pharma Rank
Latest Medison Pharma News
Jun 8, 2022
Scientist pouring a liquid in an Erlenmeyer flask with a test tube in a laboratory. Israeli-founded global pharmaceutical firm Medison Pharma , announced a multi-regional partnership with Dutch biotechnology company argenx , on Monday to commercialize its efgartigimod drug in 14 countries including Israel. Efgartigimod is approved in the United States for the treatment of adults with generalized myasthenia gravis (gMG), an autoimmune disorder that weakens multiple muscle groups throughout the body, thus impairing motor function. According to the announcement, the drug is also commonly used in Japan for the treatment of adults with gMG who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies (ISTs). The drug will also be commercialized in Poland, Hungary, Slovenia, Czech Republic, Romania, Bulgaria, Lithuania, Croatia, Slovakia, Estonia, Latvia, Greece, and Cyprus, in addition to Israel. Argenx was founded in 2008 and has since developed an “ antibody innovation ecosystem ,” or a pipeline of various immunology solutions to expedite the discovery of novel targets, disease pathways, and differentiated therapeutic antibodies. Founded in 1996 by CEO Meir Jakobsohn, Medison Pharma is one of the largest commercial partners of leading global biotech companies worldwide, providing a comprehensive range of integrated services for biotech companies looking to enter or expand their presence in Israel, Canada and Central Eastern Europe. The firm also focuses on providing patients in international markets access to highly innovative therapies and actively invests in disruptive healthcare technologies rooted in biotech and digital health verticals. “We are on a mission to help patients with severe, rare diseases get faster access to highly innovative therapies, regardless of where they live in the world,” said Jakobsohn. “By partnering with argenx, we provide a force multiplier for this breakthrough therapy, helping to save and improve the lives of patients living with generalized myasthenia gravis.” “We are proud to partner with argenx and help extend their reach to treat patients with severe autoimmune diseases in 14 countries,” said Victor Papamoniodis, VP of International Markets at Medison Pharma. “We look forward to utilizing our unique commercial platform and applying our expertise to facilitate faster access to this novel therapy for patients across all our markets.” Subscribe to NoCamels weekly newsletter and get our top stories
Medison Pharma Investments
2 Investments
Medison Pharma has made 2 investments. Their latest investment was in Keros Therapeutics as part of their Series C on March 3, 2020.
Medison Pharma Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
3/12/2020 | Series C | Keros Therapeutics | $56M | No | 3 | |
11/21/2018 | Series B |
Date | 3/12/2020 | 11/21/2018 |
---|---|---|
Round | Series C | Series B |
Company | Keros Therapeutics | |
Amount | $56M | |
New? | No | |
Co-Investors | ||
Sources | 3 |
Medison Pharma Portfolio Exits
1 Portfolio Exit
Medison Pharma has 1 portfolio exit. Their latest portfolio exit was Keros Therapeutics on April 08, 2020.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
4/8/2020 | IPO | 4 |
Date | 4/8/2020 |
---|---|
Exit | IPO |
Companies | |
Valuation | |
Acquirer | |
Sources | 4 |
Medison Pharma Partners & Customers
10 Partners and customers
Medison Pharma has 10 strategic partners and customers. Medison Pharma recently partnered with Hansa Biopharma on March 3, 2022.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
3/29/2022 | Partner | Sweden | Hansa Biopharma AB , `` Hansa Biopharma AB '' , the pioneer in enzyme technology for rare immunological conditions , and its partner Medison Pharma , a global pharma company focused on providing access to highly innovative therapies to patients in international markets , today announce that the Israeli Ministry of Health has approved Idefirix ® for desensitization treatment of highly sensitized kidney transplant patients in Israel . | 1 | |
1/9/2022 | Partner | Sweden | Hansa Biopharma provides business update including certain key financials The commercial partnership with Medison Pharma represents an important milestone for Hansa Biopharma AB as the Company expands access to imlifidase for highly sensitized patients incompatible with a deceased donor . | 1 | |
12/7/2021 | Licensor | Sweden | `` This new commercial partnership with Medison Pharma is an important milestone for Hansa Biopharma AB as it expands access to imlifidase for highly sensitized patients awaiting kidney transplants , '' says Søren Tulstrup , President & CEO of Hansa Biopharma AB . | 1 | |
10/21/2021 | Partner | ||||
3/8/2021 | Licensor |
Date | 3/29/2022 | 1/9/2022 | 12/7/2021 | 10/21/2021 | 3/8/2021 |
---|---|---|---|---|---|
Type | Partner | Partner | Licensor | Partner | Licensor |
Business Partner | |||||
Country | Sweden | Sweden | Sweden | ||
News Snippet | Hansa Biopharma AB , `` Hansa Biopharma AB '' , the pioneer in enzyme technology for rare immunological conditions , and its partner Medison Pharma , a global pharma company focused on providing access to highly innovative therapies to patients in international markets , today announce that the Israeli Ministry of Health has approved Idefirix ® for desensitization treatment of highly sensitized kidney transplant patients in Israel . | Hansa Biopharma provides business update including certain key financials The commercial partnership with Medison Pharma represents an important milestone for Hansa Biopharma AB as the Company expands access to imlifidase for highly sensitized patients incompatible with a deceased donor . | `` This new commercial partnership with Medison Pharma is an important milestone for Hansa Biopharma AB as it expands access to imlifidase for highly sensitized patients awaiting kidney transplants , '' says Søren Tulstrup , President & CEO of Hansa Biopharma AB . | ||
Sources | 1 | 1 | 1 |
Medison Pharma Team
1 Team Member
Medison Pharma has 1 team member, including current Founder, Chief Executive Officer, Meir Jakobsohn.
Name | Work History | Title | Status |
---|---|---|---|
Meir Jakobsohn | Founder, Chief Executive Officer | Current |
Name | Meir Jakobsohn |
---|---|
Work History | |
Title | Founder, Chief Executive Officer |
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.